Global Liver Disease Diagnostics Market Growth (Status and Outlook) 2025-2031

The global Liver Disease Diagnostics market size is predicted to grow from US$ 14780 million in 2025 to US$ 22580 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031.

The liver is an organ about the size of a football. It sits just under your rib cage on the right side of your abdomen. The liver is essential for digesting food and ridding your body of toxic substances. Liver disease can be inherited (genetic). Liver problems can also be caused by a variety of factors that damage the liver, such as viruses, alcohol use and obesity. Over time, conditions that damage the liver can lead to scarring (cirrhosis), which can lead to liver failure, a life-threatening condition. But early treatment may give the liver time to heal.

There are multiple causes of liver disease. While some are infective, some are genetic or autoimmune and some metabolic. This makes diagnosis difficult and often there are a battery of tests that need to be performed in order to correctly diagnose the underlying cause for the disease. Blood tests, biopsy and imaging tests are often used to check for liver disease.

Global key players of Liver Disease Diagnostics include Abbott, Roche and Thermo Fisher Scientific, etc. The top three players hold a share over 15%. North America is the largest market, has a share about 40%. In the market segment, imaging examinations (such as ultrasound, CT, MRI) dominate, accounting for about 60%, and are mainly used for screening and staging of diseases such as liver fibrosis and liver cancer. At the same time, in terms of downstream, hospitals and clinics are the largest downstream field, accounting for about 72% of the market share.

Future development trend

Early screening and early diagnosis technology breakthrough

Liquid biopsy (such as ctDNA, exosome detection) has great potential in early screening of liver cancer and can replace traditional invasive biopsy.

Multi-omics technology (genome, metabolomics) combined with AI models promotes personalized diagnosis and treatment.

Intelligent and digital integration

AI-assisted image analysis (such as liver cancer image segmentation, liver fibrosis staging) improves diagnostic efficiency.

Telemedicine and digital diagnosis and treatment platforms (such as liver disease full-process management APP) optimize patient follow-up processes.

Multidisciplinary collaboration and precision treatment

Combined medical and surgical treatment (such as the application of ERCP in complications of liver cirrhosis) and targeted drug development (such as HBV functional cure drugs) have become hot topics.

Regional market differentiation

North America is still the largest market (accounting for 40%), but Asia-Pacific (especially China) has the fastest growth rate, benefiting from policy support and the rise of local companies.

LPI (LP Information)' newest research report, the “Liver Disease Diagnostics Industry Forecast” looks at past sales and reviews total world Liver Disease Diagnostics sales in 2024, providing a comprehensive analysis by region and market sector of projected Liver Disease Diagnostics sales for 2025 through 2031. With Liver Disease Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liver Disease Diagnostics industry.

This Insight Report provides a comprehensive analysis of the global Liver Disease Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Liver Disease Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Liver Disease Diagnostics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liver Disease Diagnostics and breaks down the forecast by Purity, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liver Disease Diagnostics.

This report presents a comprehensive overview, market shares, and growth opportunities of Liver Disease Diagnostics market by product type, application, key players and key regions and countries.

Segmentation by Purity:
Imaging Tests
Blood Tests
Biopsy

Segmentation by Application:
Hospitals and Clinics
Diagnostic Centers
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Roche
Thermo Fisher Scientific
Randox Laboratories
Boston Scientific
LabCorp
Fujifilm Corporation
Siemens Healthineers
BD
Cook Medical
GE Healthcare
Philips Healthcare
Canon Medical Systems
Qiagen

Please note: The report will take approximately 2 business days to prepare and deliver.